Alkeus Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2464 Massachusetts Ave Ste 314, Cambridg...Phone Number
(800) 287-2755Website
www.alkeuspharma.comRevenue
$9.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
4
1
1
1
1
About Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. is a private, late-stage biopharmaceutical company developing a novel treatment for Stargardt disease and dry age-related macular degeneration (AMD). Stargardt disease is a progressive inherited retinal degenerative disease that causes irreversible vision loss leading to blindness. An estimated 40 to 60,000 people in the United States have this rare and serious condition. Symptoms typically begin in childhood or adolescence. There is currently no approved therapy for Stargardt disease. AMD is the number one cause of unpreventable blindness in the USA. There is currently no approved therapy for geographic atrophy, an advanced form of AMD.Explore more
Alkeus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alkeus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Alkeus Pharmaceuticals recently announced quarterly report
Check if Alkeus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Alkeus Pharmaceuticals had a recent Job posting/layoffs
Check out if Alkeus Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Alkeus Pharmaceuticals has new funding data
Alkeus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Alkeus Pharmaceuticals
Product Launch: Get notified when Alkeus Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined Alkeus Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Alkeus Pharmaceuticals
Compare insights from companies similar to Alkeus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alkeus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alkeus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alkeus Pharmaceuticals.
Alkeus Pharmaceuticals financials insights
Gather financial insights about Alkeus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$150M
Alkeus Pharmaceuticals Tech Stack
A closer look at the technologies used by Alkeus Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Alkeus Pharmaceuticals has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Trial Management Systems, and Sample Management.
Hiring Plans
Open Position
Open Position
Alkeus Pharmaceuticals News & Media
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
Alkeus Pharmaceuticals announces presentation of gildeuretinol data during Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meetingAlkeus Pharmaceuticals Announces Presentation of Investigational Oral Gildeuretinol Data During the 49th Annual Meeting of the Macula Society Being Held February 25-28
Alkeus Pharmaceuticals announces that investigational oral gildeuretinol data will be presented at the 2026 Macula Society annual meetingAlkeus Pharmaceuticals to Present Corporate Update at the 44th Annual J.P. Morgan Healthcare Conference
Alkeus Pharmaceuticals, Inc. is scheduled to present during the 44th Annual J.P. Morgan Healthcare Conference.Alkeus Pharmaceuticals Announces Gildeuretinol Data Will Be Presented During the 13th International FLORetina ICOOR Congress December 4–7 in Florence, Italy
Alkeus Pharmaceuticals announces gildeuretinol data will be presented during the 13th International FLORetina ICOOR Congress Dec. 4–7 in Florence, Italy
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Alkeus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alkeus Pharmaceuticals, Inc. is a private, late-stage biopharmaceutical company developing a novel treatment for Stargardt disease and dry age-related macular degeneration (AMD). Stargardt disease is a progressive inherited retinal degenerative disease that causes irreversible vision loss leading to blindness. An estimated 40 to 60,000 people in th... Read More
